Charles River Laboratories International, Inc. News Headlines

CRL 
$53.31
*  
0.13
0.24%
Get CRL Alerts
*Delayed - data as of Jul. 9, 2014  -  Find a broker to begin trading CRL now
Exchange: NYSE
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Charles River Laboratories: A Well-Positioned CRO Due To Blossom In Pre-Clinical Services
4/29/2014 3:26:00 PM - Seeking Alpha

Progenics Finishes Patient Enrollment - Analyst Blog
4/25/2014 7:00:01 PM - Zacks.com

Wider-than-Expected Q1 Loss at AMAG - Analyst Blog
4/25/2014 11:00:01 AM - Zacks.com

Dynavax Starts Phase III Study on Heplisav-B - Analyst Blog
4/16/2014 4:10:01 PM - Zacks.com

Regulatory Update from Impax - Analyst Blog
4/15/2014 4:55:01 PM - Zacks.com

Alimera/pSivida Seek FDA Approval for Iluvien - Analyst Blog
4/15/2014 4:45:01 PM - Zacks.com

Sanofi to File for Lemtrada Approval Again - Analyst Blog
4/8/2014 7:09:01 PM - Zacks.com

Must-know catalysts and valuation for ICON
4/4/2014 1:00:00 PM - Market Realist

Why analyst expectation of a margin compression is unreasonable
4/4/2014 9:00:00 AM - Market Realist

Market overview for CROs suggest healthy growth for ICON
4/3/2014 4:22:00 PM - Market Realist

MannKind Down on FDA's Briefing Document - Analyst Blog
3/31/2014 4:45:01 PM - Zacks.com

CHMP Backs Eli Lilly's Diabetes Drug - Analyst Blog
3/24/2014 4:30:01 PM - Zacks.com

Charles River Acquires CRO Division of Galapagos - Analyst Blog
3/14/2014 5:40:01 PM - Zacks.com

Update on Endo's Product Portfolio - Analyst Blog
3/10/2014 12:00:01 PM - Zacks.com

Regulatory Setback for Eli Lilly - Analyst Blog
3/6/2014 1:00:01 PM - Zacks.com

Halozyme's Q4 Loss Wider-Than-Expected - Analyst Blog
2/28/2014 3:43:01 PM - Zacks.com

Sanofi/Ardelyx Ink Deal - Analyst Blog
2/25/2014 8:00:01 PM - Zacks.com

Dynavax Withdraws MAA on Heplisav - Analyst Blog
2/20/2014 7:20:01 PM - Zacks.com

FDA Approves Shire's New Facility - Analyst Blog
2/19/2014 7:36:01 PM - Zacks.com

CHTP's Northera Gains FDA Approval - Analyst Blog
2/19/2014 7:20:01 PM - Zacks.com

AVEO/Astellas Terminate Agreement - Analyst Blog
2/18/2014 5:30:01 PM - Zacks.com

Quintiles Transnational Holdings (Q) Jumps: Stock Rises 5.6% - Tale of the Tape
2/14/2014 9:57:01 AM - Zacks.com

Charles River Beats Earnings Estimates in Q4 - Analyst Blog
2/12/2014 11:15:01 AM - Zacks.com

Earnings Reaction History: Charles River Laboratories, 100.0% Follow-Through Indicator, 2.3% Sensitive
2/11/2014 7:26:00 AM - MT Newswires

Will Zoetis (ZTS) Miss Estimates in Q4? - Analyst Blog
2/10/2014 1:50:01 PM - Zacks.com